Literature DB >> 32628436

Tetanus vaccine during pregnancy: data of a tertiary hospital in Turkey

Gülşah Dağdeviren1, Gökçen Örgül1, Aykan Yücel1, Dilek Şahin1.   

Abstract

Background/aim: To evaluate the prevalence of tetanus vaccination in pregnant women and determine the factors affecting the vaccination and barriers to vaccination. Materials and methods: An observational-descriptive study was conducted on 494 women who gave birth at the Etlik Zübeyde Hanım Women’s Health Training and Research Hospital, Ankara, Turkey. Participants were divided into 2 groups, vaccinated and unvaccinated. Sociodemographic characteristics, obstetric history, and prenatal care status were compared between the 2 groups.
Results: There were 242 (48.9%) and 252 (51.1%) women in the vaccinated and unvaccinated groups, respectively. The vaccination rate decreased as the number of pregnancies increased (P = 0.009). As the level of income increased, there was a statistically significant increase in the vaccination rate (P = 0.048). The status of education and having an occupation did not affect the vaccination rate (P > 0.05). The vaccination rate was higher in women with regular follow-ups when compared to those who did not get a regular follow-up (76.5% vs. 38.7%) (P = 0.001). The vaccination rate was significantly higher in women who had knowledge about tetanus vaccine during pregnancy (P < 0.005). Conclusions: All pregnant women should be encouraged to get regular antenatal care to increase vaccination rates. Health care providers should give all pregnant women detailed information about the safety, effectivity, and benefits of vaccines. This work is licensed under a Creative Commons Attribution 4.0 International License.

Entities:  

Keywords:  pregnancy; tetanus vaccine; Maternal tetanus

Year:  2020        PMID: 32628436      PMCID: PMC7775713          DOI: 10.3906/sag-2001-77

Source DB:  PubMed          Journal:  Turk J Med Sci        ISSN: 1300-0144            Impact factor:   0.973


  5 in total

1.  ACOG Committee Opinion No. 772: Immunization Implementation Strategies for Obstetrician-Gynecologists.

Authors: 
Journal:  Obstet Gynecol       Date:  2019-03       Impact factor: 7.661

2.  Maternal and neonatal tetanus elimination: validation in Punjab Province, Pakistan, November 2016.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2017-01-20

Review 3.  Vaccinations for pregnant women.

Authors:  Geeta K Swamy; R Phillips Heine
Journal:  Obstet Gynecol       Date:  2015-01       Impact factor: 7.661

4.  Tetanus immunization in pregnant women: evaluation of maternal tetanus vaccination status and factors affecting rate of vaccination coverage.

Authors:  I Maral; Z Baykan; F N Aksakal; F Kayikcioglu; M A Bumin
Journal:  Public Health       Date:  2001-09       Impact factor: 2.427

Review 5.  Maternal and neonatal tetanus.

Authors:  Martha H Roper; Jos H Vandelaer; François L Gasse
Journal:  Lancet       Date:  2007-12-08       Impact factor: 79.321

  5 in total
  3 in total

1.  Factors affecting the acceptability of COVID-19 vaccine in the postpartum period.

Authors:  Deniz Oluklu; Sule Goncu Ayhan; Dilek Menekse Beser; Derya Uyan Hendem; Eda Ozden Tokalioglu; Ezgi Turgut; Dilek Sahin
Journal:  Hum Vaccin Immunother       Date:  2021-10-29       Impact factor: 3.452

2.  Factors Associated with the Uptake of Antenatal Tetanus Toxoids Containing Vaccine by First-Time Mothers in Nigeria: Findings from the 2018 Nigerian Demographic Health Survey.

Authors:  Imran Morhason-Bello; Yusuf O Kareem; Ojone Illah; Joshua O Akinyemi; Rukiyat Abdus-Salam; Olatunji Lawal; Oluwasomidoyin Bello; Gbolahan Obajimi; Isaac F Adewole
Journal:  J Pregnancy       Date:  2022-09-14

3.  Factors associated with births protected against neonatal tetanus in Africa: Evidences from Demographic and health surveys of five African countries.

Authors:  Yigizie Yeshaw; Tadeg Jemere; Henok Dagne; Zewudu Andualem; Yonas Akalu; Reta Dewau; Achamyeleh Birhanu Teshale; Getayeneh Antehunegn Tesema; Baye Dagnew
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.